Alembic Pharmaceuticals announced that it has received an establishment inspection report (EIR) from the United States Food and Drug Administration for its oncology facility in Gujarat.
The pharma company, in a stock exchange filing, said that its oncology (injectable and oral solid) formulation facility located at Panelav in Panchmahals district of Gujarat has received the EIR from the US drug regulator.
The inspection was carried out at the pharmaceutical company’s formulation facility from February 28 to March 8. The company also said that the EIRs are in place for all of its USFDA facilities.
Meanwhile, Alembic Pharma is all set to declare its results for the fourth quarter of FY24, the company has informed the bourses. “A meeting of Board of Directors of the company will be held on May 9, inter-alia to transact the following business: To consider and approve Audited Financial Results of the Company for the quarter and financial year ended 31st March, 2024,” the company informed the bourses.
